NEW YORK, April 2 – Affymetrix subsidiary Perlegen Sciences said Monday it had raised $100 million in financing from a group of institutional and individual investors.

Following the private placement, Affymetrix will own 52 percent of Perlegen, a company launched in October to apply Affymetrix’s GeneChip technology to the entire human genome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.